Compare FA & HAE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | FA | HAE |
|---|---|---|
| Founded | 2003 | 1971 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Business Services | Medical/Dental Instruments |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.3B | 2.8B |
| IPO Year | 2021 | 1996 |
| Metric | FA | HAE |
|---|---|---|
| Price | $12.63 | $55.66 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 4 | 9 |
| Target Price | $15.67 | ★ $84.13 |
| AVG Volume (30 Days) | ★ 884.3K | 562.1K |
| Earning Date | 05-07-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 72.97 | 44.54 |
| EPS | N/A | ★ 2.46 |
| Revenue | ★ $1,574,389,000.00 | $910,373,000.00 |
| Revenue This Year | $8.42 | N/A |
| Revenue Next Year | $7.26 | $5.23 |
| P/E Ratio | ★ N/A | $22.62 |
| Revenue Growth | ★ 83.02 | N/A |
| 52 Week Low | $8.82 | $47.32 |
| 52 Week High | $19.01 | $87.32 |
| Indicator | FA | HAE |
|---|---|---|
| Relative Strength Index (RSI) | 55.22 | 37.69 |
| Support Level | $12.10 | $54.92 |
| Resistance Level | $12.78 | $56.64 |
| Average True Range (ATR) | 0.53 | 2.01 |
| MACD | -0.00 | -0.43 |
| Stochastic Oscillator | 44.44 | 9.29 |
First Advantage Corp is a provider of software and data in the Human Resources technology industry. The company provides end-to-end identity solutions, criminal background screening, credential verifications, drug and health screening, and continuous risk monitoring. It combines AI-powered proprietary technology platforms with proprietary data, primary source data, and third-party data. Its reportable segments are First Advantage Americas, First Advantage International, and Sterling. The company generates maximum revenue from the Sterling segment, which provides similar services as compared to First Advantage's Americas and International segments on a global basis. Geographically, the company generates the majority of its revenue from the United States.
Haemonetics Corp aims to improve patient care and reduce the cost of healthcare by providing medical products and solutions in the blood and plasma component collection, surgical suite, and hospital transfusion service spaces. As such, the company operates under three segments: plasma, blood center, and hospital. The company primarily emphasizes its plasma and hospital segments due to their robust growth potential, whereas the blood center segment tends to be constrained by higher competition. Product revenue is driven by demand for disposable blood component collection and processing sets and the related equipment needed for proper functionality.